

# Andrew X Zhu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1194668/publications.pdf>

Version: 2024-02-01

272  
papers

34,648  
citations

13332

70  
h-index

4741

175  
g-index

277  
all docs

277  
docs citations

277  
times ranked

26131  
citing authors

#	ARTICLE	IF	CITATIONS
1	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. <i>Gut</i> , 2022, 71, 185-193.	6.1	34
2	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
3	IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 470-470.	0.8	6
4	Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 388-388.	0.8	2
5	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated $\alpha$ -fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 423-423.	0.8	3
6	Meta-analysis of surrogate endpoints for survival in patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based regimens.. <i>Journal of Clinical Oncology</i> , 2022, 40, 483-483.	0.8	1
7	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 862-873.	1.8	568
8	Biology of IDH mutant cholangiocarcinoma. <i>Hepatology</i> , 2022, 75, 1322-1337.	3.6	20
9	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 1378-1395.	7.7	33
10	Safety, efficacy, pharmacokinetics of uliledlimab alone or combined with toripalimab in advanced solid tumor: Initial results of a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21123-e21123.	0.8	4
11	Evolution of Systemic Therapy for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 150-157.	3.6	70
12	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
13	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13
14	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	2.6	31
15	Biliary tract cancer. <i>Lancet, The</i> , 2021, 397, 428-444.	6.3	429
16	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	1.5	30
17	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 267-267.	0.8	226
18	Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 268-268.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 318-318.	0.8	0
20	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 2021, 124, 1388-1397.	2.9	39
21	Final results from ClariDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology, 2021, 39, 4069-4069.	0.8	1
22	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, e16122-e16122.	0.8	0
23	Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.. Journal of Clinical Oncology, 2021, 39, 4146-4146.	0.8	0
24	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated $\alpha$ -fetoprotein: Outcomes by treatmentâ€œemergent ascites. Hepatology Research, 2021, 51, 715-721.	1.8	5
25	Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2021, 39, 4084-4084.	0.8	1
26	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology, 2021, 39, 4074-4074.	0.8	1
27	Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 4072-4072.	0.8	2
28	Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab. Kidney International Reports, 2021, 6, 1464-1468.	0.4	9
29	IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.. Journal of Clinical Oncology, 2021, 39, 4073-4073.	0.8	52
30	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver International, 2021, 41, 2759-2767.	1.9	5
31	PLSec: A novel, liquid biomarker for HCC risk. Med, 2021, 2, 788-790.	2.2	1
32	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 991-1001.	5.1	179
33	P024â€œ..KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. , 2021, , .		1
34	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
35	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With $\lt i \gt$ IDH1 $\lt /i \gt$ Mutation. JAMA Oncology, 2021, 7, 1669.	3.4	194
36	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. The Lancet Gastroenterology and Hepatology, 2021, 6, 803-815.	3.7	205

#	ARTICLE	IF	CITATIONS
37	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110365.	1.4	24
38	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	4.2	5
39	Fast quasi-centroid molecular dynamics. <i>Journal of Chemical Physics</i> , 2021, 155, 231101.	1.2	12
40	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	5.7	112
41	Dual Programmed Death Receptor $\alpha$ 1 and Vascular Endothelial Growth Factor Receptor $\alpha$ 2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 1247-1261.	3.6	247
42	Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2020, 73, 23-29.	1.0	14
43	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1871-1884.	3.3	32
44	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020, 10, e183-e187.	1.1	2
45	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
46	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1122-1129.	0.7	29
47	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. <i>Liver Cancer</i> , 2020, 9, 440-454.	4.2	10
48	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87
49	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	0.8	350
50	Ivosidenib for advanced IDH1-mutant cholangiocarcinoma â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e371.	5.1	4
51	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
52	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2960-2970.	0.8	723
53	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6158-6167.	3.2	37
54	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , 2020, 5, e000797.	2.0	18

#	ARTICLE	IF	CITATIONS
55	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	13.9	3,828
56	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	5.1	620
57	Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. <i>Journal of Gastroenterology</i> , 2020, 55, 627-639.	2.3	23
58	Application of Image Fusion in Diagnosis and Treatment of Liver Cancer. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 1171.	1.3	21
59	Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 353-363.	1.8	235
60	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	1.9	26
61	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	3.2	67
62	Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3531-3531.	0.8	20
63	A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4519-4519.	0.8	50
64	IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4576-4576.	0.8	12
65	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4587-4587.	0.8	2
66	Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4596-4596.	0.8	7
67	Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4644-4644.	0.8	1
68	Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 476-476.	0.8	28
69	Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 518-518.	0.8	15
70	RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2020, 38, 528-528.	0.8	1
71	Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant <i>IDH1</i> advanced cholangiocarcinoma from the phase III ClarIDHy study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 539-539.	0.8	4
72	A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 547-547.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).. Journal of Clinical Oncology, 2020, 38, 549-549.	0.8	4
74	Comparing clinicopathologic feature and treatment outcome of patients who underwent surgical resection or liver transplant for nonalcoholic fatty liver disease (NAFLD)-related and non-NAFLD related hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, e16675-e16675.	0.8	0
75	Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma.. Journal of Clinical Oncology, 2020, 38, 580-580.	0.8	0
76	Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2).. Journal of Clinical Oncology, 2020, 38, 544-544.	0.8	0
77	Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors.. Journal of Clinical Oncology, 2020, 38, 515-515.	0.8	3
78	Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.. Journal of Clinical Oncology, 2020, 38, 579-579.	0.8	1
79	Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.. Journal of Clinical Oncology, 2020, 38, 569-569.	0.8	0
80	Remembering Dr. Supriya "Shoop" Saha. Oncologist, 2020, 25, 905-906.	1.9	0
81	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver International, 2019, 39, 2214-2229.	1.9	327
82	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 711-720.	3.7	161
83	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	15.2	359
84	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 282-296.	5.1	1,202
85	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	3.4	353
86	Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. JAMA Oncology, 2019, 5, 938.	3.4	2
87	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	7.7	254
88	Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. American Journal of Surgery, 2019, 218, 959-966.	0.9	14
89	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2019, 105, 64-72.	0.4	99
90	RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncology, 2019, 15, 1811-1822.	1.1	99



#	ARTICLE	IF	CITATIONS
109	External beam radiotherapy for hepatocellular carcinoma with right atrium tumor thrombus.. Journal of Clinical Oncology, 2019, 37, 328-328.	0.8	1
110	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2019, 37, 3563-3563.	0.8	2
111	Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?. Lancet Oncology, The, 2018, 19, 591-592.	5.1	12
112	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68, 723-750.	3.6	3,096
113	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2018, 4, 963.	3.4	426
114	Hepatocellular Carcinoma With Portal Venous Invasion. JAMA Oncology, 2018, 4, 669.	3.4	1
115	AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018, 67, 358-380.	3.6	2,932
116	Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer. Practical Radiation Oncology, 2018, 8, 179-184.	1.1	3
117	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282.	0.8	524
118	Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. Seminars in Radiation Oncology, 2018, 28, 332-341.	1.0	16
119	Radiotherapy for Biliary Tract Cancers. Seminars in Radiation Oncology, 2018, 28, 342-350.	1.0	14
120	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	1.3	21
121	Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 1799-1802.	0.9	45
122	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	5.1	1,816
123	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Practical Radiation Oncology, 2018, 8, 414-421.	1.1	17
124	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer, 2018, 119, 19-26.	2.9	28
125	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. Journal of Clinical Oncology, 2018, 36, 4003-4003.	0.8	77
126	A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2018, 36, 4076-4076.	0.8	101



#	ARTICLE	IF	CITATIONS
127	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. Journal of Clinical Oncology, 2018, 36, 4116-4116.	0.8	9
128	Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.. Journal of Clinical Oncology, 2018, 36, e15674-e15674.	0.8	7
129	A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS3110-TPS3110.	0.8	13
130	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4141-TPS4141.	0.8	38
131	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. Journal of Clinical Oncology, 2018, 36, 209-209.	0.8	30
132	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2018, 36, 272-272.	0.8	7
133	A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2018, 36, 270-270.	0.8	0
134	Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for local advanced gastric or Siewert II/III GEJ cancer: A retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 115-115.	0.8	0
135	Current status and evolving treatment for primary liver cancers. Chinese Clinical Oncology, 2018, 7, 47-47.	0.4	0
136	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1123-1128.	3.3	133
137	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer, 2017, 123, 1979-1988.	2.0	92
138	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. Journal of the National Cancer Institute, 2017, 109, .	3.0	82
139	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer, 2017, 81, 17-25.	1.3	64
140	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 563-573.	2.3	272
141	Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose?. Practical Radiation Oncology, 2017, 7, e323-e329.	1.1	7
142	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	2.9	416
143	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263.	7.7	384
144	Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma. Seminars in Liver Disease, 2017, 37, 259-274.	1.8	0

#	ARTICLE	IF	CITATIONS
145	New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017, 7, 943-962.	7.7	419
146	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. <i>Liver Cancer</i> , 2017, 6, 360-374.	4.2	66
147	A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4075-4075.	0.8	3
148	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4113-4113.	0.8	1
149	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4118-4118.	0.8	5
150	Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4143-TPS4143.	0.8	3
151	Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).. <i>Journal of Clinical Oncology</i> , 2017, 35, 228-228.	0.8	69
152	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 368-368.	0.8	1
153	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 386-386.	0.8	13
154	KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS503-TPS503.	0.8	29
155	KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS504-TPS504.	0.8	8
156	Clinical features and tumor mutational profile of younger versus older patients with cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 240-240.	0.8	0
157	The treatment path in hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15 Suppl 9, 1-20.	0.3	3
158	Recent developments in systemic therapy for hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15 Suppl 9, 7-13.	0.3	1
159	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 819-827.	0.6	17
160	Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4870-4879.	3.2	26
161	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2016, 6, 727-739.	7.7	126
162	CT-Guided Percutaneous Microwave Ablation of Tumors in the Hepatic Dome: Assessment of Efficacy and Safety. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 496-502.	0.2	38

#	ARTICLE	IF	CITATIONS
163	Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. <i>Oncologist</i> , 2016, 21, 594-599.	1.9	548
164	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 296-304.	1.8	26
165	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 953-959.	0.9	12
166	Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial. <i>Practical Radiation Oncology</i> , 2016, 6, e9-e16.	1.1	9
167	Liver-Directed Radiotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016, 5, 198-209.	4.2	27
168	Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. <i>Oncologist</i> , 2016, 21, 514-520.	1.9	24
169	Comparison of hepatocellular carcinoma in eastern versus western populations. <i>Cancer</i> , 2016, 122, 3430-3446.	2.0	221
170	Transarterial Chemoembolization in the Coming Era of Decreased Reimbursement for Readmissions. <i>Journal of the American College of Radiology</i> , 2016, 13, 915-921.	0.9	4
171	The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. <i>Annals of Surgical Oncology</i> , 2016, 23, 290-296.	0.7	80
172	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-468.	0.8	363
173	Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. <i>Immunotherapy</i> , 2016, 8, 299-313.	1.0	124
174	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	3.2	168
175	Clinical correlation with codon-specific mutations in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3596-3596.	0.8	1
176	Circulating biomarkers in a phase II study of hypofractionated proton beam therapy (H-PBT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4083-4083.	0.8	1
177	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 335-335.	0.8	42
178	Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 348-348.	0.8	3
179	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS478-TPS478.	0.8	2
180	Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. <i>Oncotarget</i> , 2016, 7, 75482-75491.	0.8	18

#	ARTICLE	IF	CITATIONS
181	The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. <i>Oncotarget</i> , 2016, 7, 46750-46767.	0.8	97
182	Emibetuzumab plus ramucirumab: Simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 300-300.	0.8	3
183	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 376-376.	0.8	2
184	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4145-TPS4145.	0.8	2
185	Clinicopathologic and prognostic features of hepatocellular carcinoma (HCC) due to metabolic syndrome (MS) compared to chronic liver disease (CLD) and cryptogenic causes (CC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e15616-e15616.	0.8	0
186	Radiotherapy for liver tumors. <i>Hepatic Oncology</i> , 2015, 2, 133-146.	4.2	7
187	Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy. <i>PLoS ONE</i> , 2015, 10, e0136725.	1.1	8
188	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. <i>Cell Reports</i> , 2015, 10, 1692-1707.	2.9	213
189	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1224-1235.	1.9	74
190	SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 559-566.	0.8	479
191	Chemotherapy and antiangiogenics in biliary tract cancer. <i>Lancet Oncology</i> , The, 2015, 16, 882-883.	5.1	2
192	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 859-870.	5.1	699
193	Safety and Efficacy of 70â€“150 Î¼m and 100â€“300 Î¼m Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 516-522.	0.2	62
194	Future directions in the treatment of cholangiocarcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 355-361.	1.0	29
195	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	1.9	112
196	Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2015, 22, 1344-1360.	1.3	10
197	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4020-4020.	0.8	2
198	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4077-4077.	0.8	3

#	ARTICLE	IF	CITATIONS
199	Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC).. Journal of Clinical Oncology, 2015, 33, e15149-e15149.	0.8	1
200	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated $\hat{\alpha}$ -fetoprotein (AFP) from the randomized phase III REACH study.. Journal of Clinical Oncology, 2015, 33, 232-232.	0.8	14
201	A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma.. Journal of Clinical Oncology, 2015, 33, 800-800.	0.8	9
202	A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2015, 33, e15124-e15124.	0.8	0
203	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.. Journal of Clinical Oncology, 2015, 33, 4108-4108.	0.8	0
204	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. JAMA - Journal of the American Medical Association, 2014, 312, 57.	3.8	515
205	A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Practical Radiation Oncology, 2014, 4, 316-322.	1.1	42
206	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Practical Radiation Oncology, 2014, 4, e117-e123.	1.1	4
207	Radiation Therapy for Liver Tumors: Ready for Inclusion in Guidelines?. Oncologist, 2014, 19, 868-879.	1.9	64
208	High Lung Shunt Fraction in Colorectal Liver Tumors Is Associated with Distant Metastasis and Decreased Survival. Journal of Vascular and Interventional Radiology, 2014, 25, 1604-1608.	0.2	25
209	Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. Annals of Surgical Oncology, 2014, 21, 3827-3834.	0.7	123
210	Fractal Analysis of CT Perfusion Images for Evaluation of Antiangiogenic Treatment and Survival in Hepatocellular Carcinoma. Academic Radiology, 2014, 21, 654-660.	1.3	30
211	Mutant IDH inhibits HNF-4 $\hat{\alpha}$ to block hepatocyte differentiation and promote biliary cancer. Nature, 2014, 513, 110-114.	13.7	367
212	An Emerging Role for Radiation Therapy in the Treatment of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Surgical Oncology Clinics of North America, 2014, 23, 353-368.	0.6	16
213	A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 2543-2543.	0.8	1
214	Validation of the NSABP neoadjuvant rectal score (NAR) in a prospective phase II study evaluating an experimental regimen and a standard chemoradiation cohort with molecular genotyping.. Journal of Clinical Oncology, 2014, 32, 3599-3599.	0.8	2
215	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4128-4128.	0.8	3
216	EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. Journal of Clinical Oncology, 2014, 32, 172-172.	0.8	26

#	ARTICLE	IF	CITATIONS
217	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. Journal of Clinical Oncology, 2014, 32, 230-230.	0.8	2
218	Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma.. Journal of Clinical Oncology, 2014, 32, 237-237.	0.8	6
219	Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognostic determinants and identifying therapeutic targets.. Journal of Clinical Oncology, 2014, 32, 210-210.	0.8	2
220	A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.. Journal of Clinical Oncology, 2014, 32, 255-255.	0.8	0
221	A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, TPS4157-TPS4157.	0.8	0
222	Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.. Journal of Clinical Oncology, 2014, 32, 4028-4028.	0.8	0
223	A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research, 2013, 19, 6614-6623.	3.2	139
224	Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Clinical Cancer Research, 2013, 19, 1557-1566.	3.2	65
225	New agents on the horizon in hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2013, 5, 41-50.	1.4	20
226	First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 920-928.	3.2	160
227	Current status of hepatocellular carcinoma in the United States. Chinese Clinical Oncology, 2013, 2, 45.	0.4	5
228	A phase I study of ADENSPM (N1, N11-diethylnorspermine) in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 260-260.	0.8	0
229	Mutational analysis of locally advanced rectal cancer and response to neoadjuvant chemoradiation.. Journal of Clinical Oncology, 2013, 31, 449-449.	0.8	0
230	A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 259-259.	0.8	1
231	Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2013, 31, 4125-4125.	0.8	0
232	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2013, 31, 4047-4047.	0.8	0
233	DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC): Continuum or cutpoint?. Journal of Clinical Oncology, 2013, 31, e14636-e14636.	0.8	0
234	Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues. Oncologist, 2012, 17, 1504-1507.	1.9	24

#	ARTICLE	IF	CITATIONS
235	Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives. <i>Seminars in Oncology</i> , 2012, 39, 493-502.	0.8	74
236	Sorafenib Use in Hepatocellular Carcinoma in Japan: Early Experience and Impact on Clinical Practice. <i>Clinical Drug Investigation</i> , 2012, 32, 1-2.	1.1	14
237	A Review of the Management of Hepatocellular Carcinoma: Standard Therapy and a Look to New Targets. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 275-280.	1.8	1
238	Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4112-4112.	0.8	1
239	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 301-301.	0.8	0
240	FOLFIRINOX in locally advanced and metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14615-e14615.	0.8	2
241	A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4146-TPS4146.	0.8	3
242	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4021-4021.	0.8	1
243	HCC and angiogenesis: possible targets and future directions. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 292-301.	12.5	453
244	Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities. <i>Hepatology</i> , 2011, 53, 695-704.	3.6	62
245	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 5094-5102.	2.0	177
246	Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?. <i>Annals of Surgical Oncology</i> , 2010, 17, 1247-1256.	0.7	52
247	Current Management of Gallbladder Carcinoma. <i>Oncologist</i> , 2010, 15, 168-181.	1.9	279
248	New Trends and Novel Treatment for Hepatocellular Carcinoma: A Global Perspective. <i>Oncologist</i> , 2010, 15, 1-4.	1.9	9
249	Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. <i>Lancet Oncology</i> , The, 2010, 11, 48-54.	5.1	273
250	Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 663-672.	1.9	23
251	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3027-3035.	0.8	467
252	Commentary: Sorafenib Use in Patients with Advanced Hepatocellular Carcinoma and Underlying Child-Pugh B Cirrhosis—Evidence and Controversy. <i>Oncologist</i> , 2009, 14, 67-69.	1.9	28

#	ARTICLE	IF	CITATIONS
253	Early development of sunitinib in hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2009, 9, 143-150.	1.1	28
254	Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 374-381.	3.2	20
255	Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?. BMC Medicine, 2009, 7, 42.	2.3	13
256	Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies. Cancer Journal (Sudbury, Mass ), 2009, 15, 263-268.	1.0	33
257	Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointestinal Cancer Research: GCR, 2009, 3, S28-36.	0.8	3
258	Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer, 2008, 112, 250-259.	2.0	122
259	Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2008, 13, 120-125.	1.9	151
260	Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer, 2007, 110, 581-589.	2.0	251
261	Case 13-2006. New England Journal of Medicine, 2006, 354, 1828-1837.	13.9	6
262	Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?. Oncologist, 2006, 11, 790-800.	1.9	247
263	Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemotherapy and Pharmacology, 2006, 59, 285-293.	1.1	29
264	Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2006, 24, 1898-1903.	0.8	381
265	Response to "Acute Tumor Lysis Syndrome After Thalidomide Therapy in Advanced Hepatocellular Carcinoma". Oncologist, 2006, 11, 89-89.	1.9	1
266	Combined modality treatment for rectal cancer. Seminars in Oncology, 2005, 32, 103-112.	0.8	13
267	A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. Oncologist, 2005, 10, 392-398.	1.9	47
268	Cholangiocarcinoma in association with Thorotrast exposure. Journal of Hepato-Biliary-Pancreatic Surgery, 2004, 11, 430-433.	2.0	24
269	Adjuvant therapy for pancreatic cancer: an evolving paradigm. Surgical Oncology Clinics of North America, 2004, 13, 605-620.	0.6	4
270	Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms and Their Association with 5-Fluorouracil/Leucovorin Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2004, 3, 225-234.	1.0	16



#	ARTICLE	IF	CITATIONS
271	Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. <i>Seminars in Radiation Oncology</i> , 2003, 13, 454-468.	1.0	41
272	Hepatocellular Carcinoma: Are We Making Progress?. <i>Cancer Investigation</i> , 2003, 21, 418-428.	0.6	53